{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:45:33Z","timestamp":1790743533639,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1016\/j.pharma.2008.12.005","type":"journal-article","created":{"date-parts":[[2009,2,24]],"date-time":"2009-02-24T09:25:16Z","timestamp":1235467516000},"page":"69-77","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Les inhibiteurs des kinases Aurora"],"prefix":"10.1016","volume":"67","author":[{"given":"S.","family":"Pinel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Barbault-Foucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-C.","family":"Lott-Desroches","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Astier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2008.12.005_bib1","first-page":"589","article-title":"Targeting Aurora-2 kinase in cancer","volume":"2","author":"Warner","year":"2003","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharma.2008.12.005_bib2","first-page":"330","article-title":"L\u2019inhibiteur de kinases Aurora VX680, chef de file d\u2019une nouvelle famille d\u2019agents antitumoraux","volume":"91","author":"Lavelle","year":"2004","journal-title":"Bull cancer"},{"key":"10.1016\/j.pharma.2008.12.005_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ctrv.2007.09.005","article-title":"Kinases Aurora as targets for cancer therapy","volume":"34","author":"Mountzios","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pharma.2008.12.005_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/nrm1245","article-title":"The cellular geography of kinases Aurora","volume":"4","author":"Carmena","year":"2003","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.pharma.2008.12.005_bib5","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.biocel.2005.02.021","article-title":"Kinases Aurora","volume":"37","author":"Bolanos-Garcia","year":"2005","journal-title":"Int J Biochem Cell B"},{"key":"10.1016\/j.pharma.2008.12.005_bib6","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bmcl.2006.10.086","article-title":"Structural basis for the inhibition of Aurora A kinase by a novel class of high affinity disubstituted pyrimidine inhibitors","volume":"17","author":"Tari","year":"2007","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.pharma.2008.12.005_bib7","unstructured":"Meijer L. Le cycle de division cellulaire et sa r\u00e9gulation. Bull Cancer 2006;41\u201353 [hors s\u00e9rie]"},{"key":"10.1016\/j.pharma.2008.12.005_bib8","unstructured":"http:\/\/www.snv.jussieu.fr\/bmedia\/Mitose\/m5.htm. Consult\u00e9 le 1eravril 2008, mise en ligne\u00a0: d\u00e9cembre 2000, derni\u00e8re modification\u00a0: 17 janvier 2002."},{"key":"10.1016\/j.pharma.2008.12.005_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.5507\/bp.2008.004","article-title":"Aurora kinases: structure, functions and their association with cancer","volume":"152","author":"Kollaredy","year":"2008","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"10.1016\/j.pharma.2008.12.005_bib10","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1093\/embo-reports\/kvf095","article-title":"APC\/Fizzy-Related targets Aurora-A kinase for proteolysis","volume":"3","author":"Castro","year":"2002","journal-title":"EMBO Rep"},{"key":"10.1016\/j.pharma.2008.12.005_bib11","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.molcel.2005.03.031","article-title":"Mechanism of Aurora B activation by INCENP and inhibition by hesperadin","volume":"18","author":"Sessa","year":"2005","journal-title":"Mol Cell"},{"key":"10.1016\/j.pharma.2008.12.005_bib12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.ceb.2003.10.013","article-title":"Mitotic mechanics: the Auroras into view","volume":"15","author":"Andrews","year":"2003","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.pharma.2008.12.005_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1159\/000015089","article-title":"Identification and characterization of STK12\/Aik2: a human gene related to Aurora of Drosphila and yeast IPL1","volume":"82","author":"Kimura","year":"1998","journal-title":"Cytogenet Cell Genet"},{"key":"10.1016\/j.pharma.2008.12.005_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2008.01.005","article-title":"Kinases Aurora as an anticancer target","volume":"262","author":"Ikezoe","year":"2008","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharma.2008.12.005_bib15","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1089\/dna.1998.17.823","article-title":"Protein kinase profile of sperm and eggs: cloning and characterization of two novels testis specific protein kinases (AIE1, AEI2) related to yeast and fly chromosome segregation regulators","volume":"17","author":"Tseng","year":"1998","journal-title":"DNA Cell Biol"},{"key":"10.1016\/j.pharma.2008.12.005_bib16","doi-asserted-by":"crossref","unstructured":"Montembault E, Prigent C. Kinases Aurora: therapeutic potential. Drugs of the future. 2005:30. http:\/\/mandrake.med.univ-rennes1.fr\/Intranet\/projet_labo\/publi_pdf\/AURORA %20 KINASES:%20THERAPEUTIC\u00a0%20POTENTIAL.pdf consult\u00e9 le 16avril 2008.","DOI":"10.1358\/dof.2005.030.01.875304"},{"key":"10.1016\/j.pharma.2008.12.005_bib17","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbrc.2006.11.004","article-title":"Aurora kinase inhibition downregulates NFKB and sensitises tumour cells to chemotherapeutic agents","volume":"352","author":"Sun","year":"2007","journal-title":"Biochem Bioph Res Co"},{"key":"10.1016\/j.pharma.2008.12.005_bib18","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1038\/sj.onc.1201065","article-title":"A putative serine\/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines","volume":"14","author":"Sen","year":"1997","journal-title":"Oncogene"},{"key":"10.1016\/j.pharma.2008.12.005_bib19","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1023\/A:1023789416385","article-title":"The kinases Aurora: role in cell transformation and tumorigenesis","volume":"22","author":"Katayama","year":"2003","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.pharma.2008.12.005_bib20","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/ng1279","article-title":"Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53","volume":"36","author":"Katayama","year":"2004","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharma.2008.12.005_bib21","doi-asserted-by":"crossref","first-page":"52175","DOI":"10.1074\/jbc.M406802200","article-title":"Aurora-A abrogation of p53 DNA binding and transactivation activity by phosphorylation of serine 215","volume":"279","author":"Liu","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharma.2008.12.005_bib22","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1158\/1078-0432.CCR-1057-03","article-title":"Overexpression and amplification of Aurora-A in hepatocellular carcinoma","volume":"10","author":"Jeng","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2008.12.005_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1535-6108(02)00235-0","article-title":"AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol","volume":"3","author":"Anand","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.pharma.2008.12.005_bib24","first-page":"5168","article-title":"Increased mitotic phosphorylation of histone H3 attributable to AIM-1\/Aurora-B overexpression contributes to chromosome number instability","volume":"62","author":"Ota","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2008.12.005_bib25","first-page":"4811","article-title":"Multinuclearity and increased ploidy caused by overexpression of the Aurora and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells","volume":"58","author":"Tatsuka","year":"1998","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2008.12.005_bib26","unstructured":"http:\/\/www.crimsoncanary.com\/Documents\/Aurora_Kinase.pdf Consult\u00e9 le 16avril2008."},{"key":"10.1016\/j.pharma.2008.12.005_bib27","unstructured":"http:\/\/www.pnas.org\/content\/104\/10\/4106\/suppl\/DC1 Consult\u00e9 le 12novembre2008."},{"key":"10.1016\/j.pharma.2008.12.005_bib28","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1016\/j.jmgm.2007.11.003","article-title":"Molecular docking\/dynamics studies of Aurora A kinase inhibitors","volume":"26","author":"Talele","year":"2008","journal-title":"J Mol Graph Model"},{"key":"10.1016\/j.pharma.2008.12.005_bib29","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm1003","article-title":"VX-680, a potent and selective small-molecule inhibitor of the Kinases Aurora suppresses tumor growth in vivo","volume":"10","author":"Harrington","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.pharma.2008.12.005_bib30","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.3009","article-title":"A phase I clinical and pharmacokinetic trial of the Aurora kinase inhibitor MK-0457 in cancer patients","volume":"24","author":"Rubin","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2008.12.005_bib31","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-07-2179","article-title":"Aurora kinases as anticancer drug targets","volume":"14","author":"Gautshi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2008.12.005_bib32","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2008.12.005_bib33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.canlet.2006.12.004","article-title":"Structural basis for potent inhibition of the kinases Aurora and a T315I multi-drug resistant mutant form of Abl kinase by VX-680","volume":"251","author":"Cheetman","year":"2007","journal-title":"Cancer Lett"},{"key":"10.1016\/j.pharma.2008.12.005_bib34","doi-asserted-by":"crossref","first-page":"5437","DOI":"10.1158\/1078-0432.CCR-07-4922","article-title":"Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth","volume":"14","author":"Lin","year":"2008","journal-title":"Clin Cancer Res."},{"key":"10.1016\/j.pharma.2008.12.005_bib35","doi-asserted-by":"crossref","first-page":"51786","DOI":"10.1074\/jbc.M306275200","article-title":"Aurora \u2013a kinase maintains the fidelity of early and late mitotic events in Hela cells","volume":"278","author":"Marumoto","year":"2003","journal-title":"J Biol. Chem."},{"key":"10.1016\/j.pharma.2008.12.005_bib36","doi-asserted-by":"crossref","first-page":"4513","DOI":"10.1128\/MCB.02364-06","article-title":"MLN8054, a small-molecule inhibitor of Aurora-A, causes spindle pole and chromosome congression defects leading to aneuploidy","volume":"12","author":"Hoar","year":"2007","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.pharma.2008.12.005_bib37","doi-asserted-by":"crossref","first-page":"5362","DOI":"10.1158\/0008-5472.CAN-07-0122","article-title":"Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity","volume":"67","author":"LeRoy","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2008.12.005_bib38","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1073\/pnas.0608798104","article-title":"Antitumor activity of MLN8054, an orally small-molecule Aurora A kinase","volume":"104","author":"Manfredi","year":"2007","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.pharma.2008.12.005_bib39","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1021\/jm061335f","article-title":"Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of Aurora B kinase","volume":"50","author":"Mortlock","year":"2007","journal-title":"J Med Chem"},{"key":"10.1016\/j.pharma.2008.12.005_bib40","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3324\/haematol.12148","article-title":"Effects of the Aurora kinase inhibitors AZD1152-HQPA and ZM447439 on growth arrest and polyploidy in acute myeloid leukaemia cell lines and primary blasts","volume":"93","author":"Walsby","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.pharma.2008.12.005_bib41","doi-asserted-by":"crossref","first-page":"3244","DOI":"10.1038\/sj.onc.1210990","article-title":"Enhancement of radiation response in p-53-deficient cancer cells by the Aurora-B kinase inhibitor AZD1152","volume":"27","author":"Tao","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.pharma.2008.12.005_bib42","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1365-2141.2007.06913.x","article-title":"The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma","volume":"140","author":"Evans","year":"2008","journal-title":"Br J Haemotol"},{"key":"10.1016\/j.pharma.2008.12.005_bib43","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1182\/blood-2007-02-073700","article-title":"AZD1152, a novel and selective Aurora B kinase inhibitor, induces growh arrest, apoptosis, and sensibilization for tubulin depolymerising agent or topoisomerase II inhibitor in human acute leukemia cells in vitro and in vivo","volume":"110","author":"Yang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2008.12.005_bib44","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2006.24.18_suppl.3008","article-title":"Phase 1 and pharmacological study of the novel Aurora kinase inhibitor AZD1152","volume":"24","author":"Schellens","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.pharma.2008.12.005_bib45","doi-asserted-by":"crossref","first-page":"7987","DOI":"10.1158\/0008-5472.CAN-07-1825","article-title":"Crystal structure of the T315I Abl mutant in complex with the kinases Aurora inhibitor PHA-739358","volume":"67","author":"Modugno","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2008.12.005_bib46","doi-asserted-by":"crossref","first-page":"4355","DOI":"10.1182\/blood-2007-09-113175","article-title":"Simultaneous targeting of kinases Aurora and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I","volume":"111","author":"Gontarewicz","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.pharma.2008.12.005_bib47","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1158\/1078-0432.CCR-07-1893","article-title":"Combination of vascular endothelial growth factor receptor: platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy","volume":"14","author":"Timke","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pharma.2008.12.005_bib48","unstructured":"http:\/\/www.nci.nih.gov\/Templates\/drugdictionary.aspx?CdrID=489092 Consult\u00e9 le 12novembre2008."},{"key":"10.1016\/j.pharma.2008.12.005_bib49","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1471-2407-7-49","article-title":"Tyrosine kinase inhibitor SU6668 represses chondrosarcoma growth via antiangiogenesis in vivo","volume":"7","author":"Klenke","year":"2007","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharma.2008.12.005_bib50","doi-asserted-by":"crossref","first-page":"6919","DOI":"10.1158\/0008-5472.CAN-05-0574","article-title":"Proteomic characterization of the angiogenesis inhibitor SU6668 reveals multiple impacts on cellular kinase signalling","volume":"65","author":"Godl","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.pharma.2008.12.005_bib51","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s10555-007-9074-y","article-title":"Tumor-host interaction in the optimization of paclitaxel-based combination therapies with vascular targeting compounds","volume":"26","author":"Giavazzi","year":"2007","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.pharma.2008.12.005_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11547-007-0144-6","article-title":"Pathological animal models in the experimental evaluation of tumour microvasculature with magnetic resonance imaging","volume":"112","author":"Faccioli","year":"2007","journal-title":"Radiol Med"},{"key":"10.1016\/j.pharma.2008.12.005_bib53","first-page":"376","article-title":"Effect of endostatine and SU6668 combined with 5-FU on human colon cancer xenograft in nude mice","volume":"11","author":"Zeng","year":"2008","journal-title":"Zonghua Wei Chang Wai Ke Za Zhi"},{"key":"10.1016\/j.pharma.2008.12.005_bib54","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1200\/jco.2008.26.15_suppl.2518","article-title":"Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor refractory leukaemia","volume":"26","author":"Foran","year":"2008","journal-title":"Journal of clinical oncology"},{"key":"10.1016\/j.pharma.2008.12.005_bib55","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-07-0067","article-title":"\u00c0 novel treatment strategy targeting kinases Aurora in acute myelogenous leukemia","volume":"6","author":"Ikezoe","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.pharma.2008.12.005_bib56","first-page":"1091","article-title":"Aurora kinase inhibitor ZM447439 blocks chromosome-induced spindle assembly, the completion of chromosome condensation, and the etablishment of the spindle integrity checkpoint in xenopus egg extracts","volume":"10","author":"Gadea","year":"2004","journal-title":"Mol Cell Biomech"}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450909000042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T23:28:04Z","timestamp":1757719684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450909000042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0003450909000042"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2008.12.005","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Les inhibiteurs des kinases Aurora","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2008.12.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2009 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}